nanoparticle epirubicin (NC-6300) / NANO MRNA - LARVOL DELTA

Translational nanomedicine potentiates immunotherapy in sarcoma by normalizing the microenvironment. (PubMed, J Control Release) - "Furthermore, NC-6300 is more effective than the maximum tolerated dose of doxorubicin in increasing the tumor growth delay induced by anti-PD-L1 antibody. As a result, the combination with anti-PD-L1 antibody increased the intratumor density and proliferation of T cells. In conclusion, NC-6300 potentiates immune checkpoint inhibition in sarcoma, and normalization of the tumor microenvironment should be investigated when developing nanocarrier-based chemo-immunotherapy regimens."

Journal • Fibrosarcoma • Fibrosis • Immune Modulation • Immunology • Inflammation • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma. (PubMed, Oncologist) - P1b/2 | "NC-6300 was well tolerated, showing promising activity in angiosarcoma patients without prior anthracycline treatment. NC-6300 warrants further investigation (ClinicalTrials.gov Identifier: NCT03168061)."

Journal • Angiosarcoma • Fatigue • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Thrombocytopenia

[VIRTUAL] Results of NC-6300 (nanoparticle epirubicin) in an expansion cohort of patients with angiosarcoma. (ASCO 2021) - P1b/2 | "Promising anti-tumor activity was observed in this cohort of patients with cutaneous and non-cutaneous angiosarcoma . The safety profile of this expansion cohort was consistent with previous clinical study results of NC-6300 . Our study results warrant further development of NC-6300 for angoisarcoma."

Clinical • Anemia • Angiosarcoma • Dental Disorders • Hematological Disorders • Infectious Disease • Leukopenia • Neutropenia • Non-melanoma Skin Cancer • Oncology • Respiratory Diseases • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Stomatitis • Thrombocytopenia

"#CROI2021 - Bollettino Conclusivo dall'edizione virtuale della conferenza internazionale https://t.co/k912yrSYG8 via @Lila_Italia e @aidsmap" (@Lila_Italia)

Cancer-Targeted Controlled Delivery of Chemotherapeutic Anthracycline Derivatives Using Apoferritin Nanocage Carriers. (PubMed, Int J Mol Sci) - "Anthracycline drugs, including doxorubicin (DOX), epirubicin (EPI), daunorubicin (DAU), and idarubicin (IDA), with lipophilicity P from 0.8 to 15, were investigated...The in vitro cytotoxicity/growth inhibition tests and flow cytometry corroborate high apoptotic activity of APO(drugs) against targeted MDA-MB-231 adenocarcinoma and HeLa cells, and low activity against healthy MCF10A cells, demonstrating targeting ability of nanodrugs. A model for molecular interactions between anthracyclines and APO nanocarriers was developed, and the relationships derived compared with experimental results."

Journal • Oncology

Simultaneous electrochemical determination of nuc and mecA genes for identification of methicillin-resistant Staphylococcus aureus using N-doped porous carbon and DNA-modified MOF. (PubMed, Mikrochim Acta) - "Two electroactive dyes, methylene blue (MB) and epirubicin (EP), were encapsulated in UiO-66-NH, respectively, and were locked by the hybrid double-stranded DNA...Besides, MRSA and SA can also be distinguished. This sensor has great potential in practical applications."

Journal

A Phase 1b Dose-Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma. (PubMed, Clin Cancer Res) - "NC-6300 was well tolerated with a manageable side effect profile, despite the MTD and RP2D being higher than conventional epirubicin doses. A signal of preliminary activity was observed in angiosarcoma. NC-6300 warrants further investigation in patients with advanced solid tumors, including sarcoma."

Clinical • Journal • P1 data • Dental Disorders • Hematological Disorders • Immunology • Neutropenia • Oncology • Osteosarcoma • Sarcoma • Stomatitis • Thrombocytopenia • Uterine Cancer

Preparation and pharmacokinetics of bifunctional epirubicin-loaded micelles. (PubMed, Pharmazie) - "The AUC calculated for the EPI-FIDCR formulation was 159.5-fold compared with that of EPI-Free, based on its improved stability and prolonged blood circulation time. The EPI-FIDCR enables both fluorescence imaging and controlled drug-release, exhibits prolonged systematic circulation time and has potential for the treatment of cancer."

Journal • PK/PD data • Oncology

Reinforcement of antitumor effect of micelles containing anticancer drugs by binding of an anti-tissue factor antibody without direct cytocidal effects. (PubMed, J Control Release) - "To increase the antitumor effect of these safer micelle formulations, epirubicin-incorporating polymer micelles (NC-6300) conjugated with monoclonal antibodies (mAbs) have been prepared. On the other hand, immunomicelles conjugated to anti-HER2 mAb did not exert significant antitumor activity toward HER2-positive stomach cancer relative to the combined use of anti-HER2 mAb and NC-6300. Thus, this immunomicelle-based strategy may be useful for antibodies that target cancer as pilot molecules even when the antibodies themselves do not have an antitumor effect."

Journal

Development and characterization of folic acid-functionalized apoferritin as a delivery vehicle for epirubicin against MCF-7 breast cancer cells. (PubMed, Artif Cells Nanomed Biotechnol) - "UV-vis spectroscopy, fluorescence spectroscopy, circular dichroism (CD) and transmission electron microscopy (TEM) were utilized for structural characterization of the HsAFr-Epr and HsAFr-Epr-FA complexes. The comparison of the anti-cancer activities across the HsAFr-Epr-FA complex and the free Epr drug was performed using the MTT viability assay on MCF-7."

Journal

Hierarchically Nanostructured Fe₃O₄/C Composite as a Promising Magnetic Targeted Drug Nanocarrier. (PubMed, J Nanosci Nanotechnol) - "...In particular, the composite nanospheres deliver a large loading content (85.8%) of epirubicin hydrochloride (EPI), resulting from their unique composition and microstructure. More importantly, the release of EPI from the EPI-loaded magnetic carrier (Fe₃O₄/C-EPI) may be enhanced by both a slightly acidic environment and a rotating magnetic field induced by a simple motor-driven magnet system. The above favorable properties make the hierarchical Fe₃O₄/C composite sample a promising candidate for magnetic targeting nanocarriers of EPI."

Journal

Sonodynamic Therapy With Anticancer Micelles and High-Intensity Focused Ultrasound in Treatment of Canine Cancer. (PubMed, Front Pharmacol) - "To validate its usefulness, we performed a clinical trial of SDT using an anticancer micelle (NC-6300) and our HIFU system in four pet dogs with spontaneous tumors, including chondrosarcoma, osteosarcoma, hepatocellular cancer, and prostate cancer. The fact that no adverse events were observed, suggests the usefulness of SDT."

Journal

Function of Epirubicin-Conjugated Polymeric Micelles in Sonodynamic Therapy. (PubMed, Front Pharmacol) - "The combinatory use of high-intensity focused ultrasound (HIFU) and epirubicin (EPI)-conjugated polymeric micellar nanoparticles (NC-6300) is thought to be a less invasive and more efficient method of cancer therapy. In conclusion, drug-conjugated micellar nanoparticles are more desirable for SDT because of accelerated ROS production and drug protection from ROS. Furthermore, a combination of NC-6300 and TP-HIFU is useful for minimally invasive cancer therapy with cooperative effects of HIFU-derived features, antitumor activity of EPI, and increased ROS generation to cause damage to cancer cells."

Journal